An update on vitamin D signaling and cancer by Carlberg, Carsten & Muñoz, Alberto
Seminars in Cancer Biology xxx (xxxx) xxx
Please cite this article as: Carsten Carlberg, Alberto Muñoz, Seminars in Cancer Biology, https://doi.org/10.1016/j.semcancer.2020.05.018
Available online 30 May 2020
1044-579X/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Review 
An update on vitamin D signaling and cancer 
Carsten Carlberg a,*, Alberto Muñoz b 
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A B S T R A C T   
A low vitamin D status is associated with an increased risk of various cancers, such as of colon, breast, prostate 
and hematological cells. The biologically most active vitamin D metabolite 1α,25-dihydroxyvitamin D3 (1,25 
(OH)2D3) is a high affinity ligand of the transcription factor vitamin D receptor (VDR). 1,25(OH)2D3 induces via 
VDR changes to the epigenome of healthy and neoplastic cells and in this way influences their transcriptome. 
Ligand-activated VDR binds to more than 10,000 loci within the human genome and affects the transcription of 
some 1000 target genes in a large proportion of human tissues and cell types. From the evolutionary perspective, 
the prime role of vitamin D was probably the control of energy metabolism later shifting to modulate innate and 
adaptive immunity as well as to regulate calcium and bone homeostasis. Since rapidly growing immune and 
cancer cells both use the same pathways and genes for controlling their proliferation, differentiation and 
apoptosis, not surprisingly, vitamin D signaling changes these processes also in neoplastic cells. Thus, anti-cancer 
effects of vitamin D may derive from managing growth and differentiation in immunity. This review provides an 
update on the molecular basis of vitamin D signaling, i.e., the effects of 1,25(OH)2D3 on the epigenome and 
transcriptome, and its relationship to cancer prevention and therapy.   
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1. Introduction 
Cancer is the overarching term describing a multitude of very 
heterogenous diseases that have in common displaying uncontrolled 
overgrowth of cells in any tissue of an individual [1]. The molecular 
basis of cancer is the accumulation of point mutations and copy number 
variations, such as amplification and deletions or big chromosomal al-
terations like translocations and aneuploidies, that enhance the activity 
of oncogenes and decrease that of tumor suppressor genes [2,3]. These 
genomic instabilities are modulated by epigenetic changes through 
direct actions of chromatin modifying enzymes as well as via indirect 
effects of transcription factors [4]. Both chromatin modifiers and tran-
scription factors are often found at the endpoint of signal transduction 
cascades that are stimulated by various intra- and extracellular signals. 
Changes of the epigenome are triggered by signals of the cellular envi-
ronment, such as nutrients, toxins and inflammation-related cytokines 
and chemokines [5]. Thus, epigenetic changes can have both detri-
mental as well as beneficial effects on cancer onset and progression. 
Fig. 1. Vitamin D signaling. Production of vitamin D3 and its metabolites 25(OH)D3 and 1,25(OH)2D3 (A). VDR (green) binds accessible genomic DNA in complex 
with a partner protein (RXR or others, blue) (B). VDR’s DNA binding is supported by the pioneer factors PU.1, CEBPA and/or GABPA. The genomic region that can be 
influenced by 1,25(OH)2D3 (via binding to VDR) is restricted by CTCF proteins defining left and right TAD borders. Schematic representation of a Voronoi tessellation 
[55] displaying five TAD classes of the most prominently enriched biological processes (C). The most relevant attributes are the number of persistent and transient 
VDR sites and were chosen for the x and y axis, respectively. 
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The worldwide increase in life expectancy raises the rates of cancer 
morbidity and mortality, with some 18 million new cancer cases and 
nearly 10 million cancer deaths in 2018 [6]. The costly treatment of the 
disease, such as surgery, radiation therapy and chemotherapy, is a 
financial burden for the healthcare systems of developed countries and is 
even not easily accessible to the majority of the population in developing 
countries [7]. Thus, there is urgent need for anti-cancer options that 
combine preventive with therapeutic potentials, ideally at low cost. 
In this context vitamin D3 (also called cholecalciferol) has gained 
significant attention as an inexpensive and readily accessible natural 
compound [8]. The main source of this seco-steroid is its non-enzymatic 
production in human skin from UV-B exposed 7-dehydrocholesterol, 
which is an abundant direct cholesterol precursor (Fig. 1A) [9]. Circu-
lating vitamin D3 from endogenous production as well as from dietary 
uptake is converted in the liver to 25-hydroxyvitamin D3 (25(OH)D3, 
also called calcidiol). The serum concentration of this most stable 
vitamin D metabolite is used as biomarker for the vitamin D status of a 
person [10]. The natural way of producing vitamin D3 via UV-B exposure 
of the skin should be used with precaution, since excessive sun bathing 
leads to sunburn and may cause different types of skin cancer. Unfor-
tunately, only a limited number of foods, such as the fatty fishes salmon, 
tuna and mackerel, contain substantial amounts of vitamin D3. More-
over, only in a few countries foods, such as milk, dairy products, orange 
juice and margarines, are regularly fortified with vitamin D2 (also called 
ergocalciferol) or vitamin D3 [11]. This makes direct supplementation 
with vitamin D3 (800–4000 IU, i.e., 20− 100 μg/day) an alternative 
strategy for optimizing the vitamin D status to 25(OH)D3 serum levels of 
75–150 nM (i.e., 30− 60 ng/mL) [12]. 
The hydroxylation of 25(OH)D3 at carbon 1, taking place primarily 
in the kidneys and also in several types of epithelial and immune cells, 
leads to 1,25(OH)2D3 (also called calcitriol, Fig. 1A), which is the high- 
affinity ligand of the transcription factor VDR [13]. In this way, in the 
nucleus vitamin D has a direct effect on gene regulation and via the 
actions of VDR it also affects the epigenome (Fig. 1B) [14]. Moreover, in 
a variable cell-type and -context a proportion of VDR molecules locate in 
the cytosol, where they mediate ligand-dependent, rapid modulatory 
effects on signaling pathways affecting enzymes, kinases, phosphatases 
and ion channels. These effects do not require changes in gene tran-
scription and are called non-genomic actions [15]. Thus, vitamin D3 and 
its metabolites may be ideal compounds for modulating intracellular 
pathways with impact on cellular growth, differentiation and apoptosis. 
This review will provide an update of excellent previous surveys 
[16–18] on the molecular and cellular basis of vitamin D signaling and 
its relationship to cancer prevention and therapy. 
2. Linking vitamin D with cancer prevention 
Already 40 years ago, an epidemiological study suggested that 
vitamin D may be protective against colorectal cancer (CRC), since 
increased sun (UV-B) exposure as well as a life at lower latitudes (both 
causing higher vitamin D3 formation) leads to a lower incidence for this 
type of cancer [19]. Interestingly, at about the same time 1,25(OH)2D3 
was found to have in vitro an anti-proliferative effect on melanoma cells 
[20]. In general, a low vitamin D status seems to be associated with a 
higher cancer incidence [21]. A number of vitamin D intervention trials 
with different types of cancer, but not all, confirmed this observation 
and most convincing data were presented for CRC [22–24]. Moreover, 
there are many in vitro studies and a few in vivo data indicating that 
vitamin D is also effective against breast and prostate cancer as well as 
leukemia and lymphoma. A final answer concerning the impact of 
vitamin D on cancer prevention was expected from randomized control 
trials. 
The large randomized control trial VITAL [25] had enrolled 25,871 
participants without a history of cancer and used 2000 IU (50 μg) 
vitamin D3 per day for primary prevention of cancer within a period of 5 
years. Although the primary analysis of that study did not report any 
significant reduction in the risk of cancer mortality, a secondary analysis 
suggested a benefit of vitamin D3 after exclusion of early follow-up data 
and for subgroups of individuals in cancer incidence and/or mortality 
[25,26]. Similarly, a meta-analysis [27] of three other randomized 
control trials [28–30], each of them having a null result, found that 
vitamin D3 supplementation leads to a significantly lower total cancer 
mortality. In this context, the concept of a personalized vitamin D 
response index [31] may be taken into account. As shown with Finnish 
cohorts [32,33] about 25 % of the population seem to be low responders 
to vitamin D supplementation, i.e., these persons need higher daily doses 
of vitamin D3, in order to reach the full clinical benefit. So far, partici-
pants of randomized control trials have not been stratified for low, mid 
and high vitamin D responders. Moreover, many study subjects were 
recruited with a rather high vitamin D status, i.e., they may have been in 
the range of vitamin D sufficiency and did not need further 
supplementation. 
In summary, a stratification of the participants, a better design 
including the analysis of health outcomes in relation to changes in in-
dividual serum 25(OH)D3 values and an adequate duration of the study/ 
follow-up as well as the type of statistical analysis majorly influence the 
final conclusion taken from randomized control trials on vitamin D [34]. 
3. Vitamin D and its receptor 
The 48 nuclear receptors encoded by the human genome form an 
unusual superfamily of transcription factors, since the majority of these 
proteins can be activated by small lipophilic molecules in the range of 
the molecular mass and volume of cholesterol [35]. Prominent members 
of the superfamily are the endocrine receptors for estrogen, progester-
one and cortisol (estrogen receptors (ERs), progesterone receptor (PR) 
and glucocorticoid receptor) as well as the adopted orphan receptors for 
fatty acids and oxysterols (peroxisome proliferator-activated receptors 
and liver X receptors) [36]. Nuclear receptors are characterized by a 
structurally conserved ligand-binding domain [37]. In case of VDR, 
some 40 mostly non-polar amino acids within this domain form a 
ligand-binding pocket that fixes 1,25(OH)2D3 or its synthetic analogs 
with high specificity [38]. Accordingly, VDR is the only protein that 
binds at sub-nanomolar concentrations (KD 0.1 nM) the biologically 
most active form of vitamin D3 [39], i.e., VDR is the exclusive mediator 
of the effects of physiological concentrations of 1,25(OH)2D3. 
The high-affinity 1,25(OH)2D3-binding VDR protein evolved already 
some 550 million years ago in a boneless vertebrate [40]. The initial 
function of VDR was most likely the regulation of energy metabolism 
[41]. The fact that the innate immune system and the developing 
adaptive immunity require substantial amounts of energy [42] seem to 
have served as a starting point how vitamin D and its receptor got via the 
control of immunometabolism a modulatory impact on immunity [43]. 
Since immune cells are the most rapidly growing cells of the body, the 
functions of vitamin D also extended to the control of cellular prolifer-
ation, differentiation and apoptosis [44]. Some 400 million years ago 
some fish species left the calcium-rich ocean and populated the 
calcium-poor land, where they were exposed to gravitation making a 
more stable skeleton essential [45]. At that time vitamin D and VDR 
gained the additional role of regulating calcium homeostasis, which is 
indispensable for proper bone formation. In this physiological function 
vitamin D obtained key importance [46], i.e., in contrast to its previous 
tasks no other regulatory molecules are able to replace vitamin D. This 
explains why the prime phenotype of vitamin D deficiency is bone 
malformation, such as occurring in rickets [47]. Nevertheless, the rather 
ubiquitous expression of the VDR gene in more than half of the 400 
human tissues and cell types (www.proteinatlas.org/ENSG00000 
111424-VDR/tissue) indicates that vitamin D and its receptor have a 
wider physiological role than the regulation of calcium homeostasis 
[48]. 
The VDR cistrome, i.e., the genome-wide binding pattern of the 
transcription factor, is determined via the next-generation sequencing 
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method chromatin immunoprecipitation sequencing (ChIP-seq) [49]. 
This cistrome had been obtained in immortalized primary human cell 
types, such as B lymphocytes (GM10855, GM10861 and cells from 30 
other HapMap individuals) [50,51], hepatic stellate cells (LX2) [52] and 
prostate epithelial cells (RWPE1) [53], as well as in cell lines derived 
from acute monocytic leukemia (AML) of a 1-year-old male (THP-1) [54, 
55] and CRC of a 58-year-old female (LS180) [56]. In addition, VDR 
ChIP-seq had been performed with epithelial stem cell-derived organo-
ids of normal tissue of CRC patients [57] as well as with primary normal 
fibroblasts (NFs) of healthy donors [58] and kidney cortex of human 
cadavers [59]. From all investigated cellular models, leukemia cells 
(THP-1) have been studied most extensively for the molecular mecha-
nisms of vitamin D signaling [60]. VDR binding sites drastically 
up-regulating the gene CYP24A1 (cytochrome P450 family 24 subfamily 
A member 1) in THP-1 cells, normal organoids of three different pairs of 
CRC patients and LS180 cells are displayed as a representative example 
(Fig. 2A). CYP24A1 is the key vitamin D catabolizing enzyme and reg-
ulates the levels of 25(OH)D3 and 1,25(OH)2D3 [61], the expression of 
which is mostly negatively associated with cancer prognosis [62]. 
Depending on the cell type, the VDR cistrome comprises many 
thousand VDR binding sites spreading tissue-specifically over the human 
genome [63]. This is the most likely explanation why cell types differ 
majorly in their set of vitamin D target genes [64–66]. However, one 
common observation in all cell types is that a stimulation with 1,25 
(OH)2D3 leads to a 2- to 10-fold increase in genome-wide VDR binding 
events [63]. In an average normal or malignant human cell, the VDR 
cistrome is formed by some 10,000 genomic loci. This is far more than 
the average number of vitamin D target genes, which is in the order of 
200–1000 genes per cell type [57,64–67], i.e., not all VDR binding sites 
seem to have an impact on gene regulation. However, there are a few 
hundred VDR loci, on which after ligand stimulation receptor occupancy 
changes significantly over time while they are always bound to their loci 
[55]. These persistent VDR binding sites serve as primary contact points 
for the communication of vitamin D with the human genome, i.e., they 
act as “hotspots” of vitamin D signaling. In contrast, other VDR sites are 
only transiently occupied or used exclusively in later steps of the gene 
activation cascade. 
Taken together, vitamin D-triggered binding of VDR to the human 
genome is the most pronounced and well-understood epigenome-wide 
effect of 1,25(OH)2D3 [14]. 
Fig. 2. VDR binding and epigenomic profiles in the region of vitamin D target genes. The IGV browser [201] was used to display the epigenomic profiles at 
enhancer and TSS regions of the vitamin D target genes CYP24A1 (A) and CDKN1A (B). VDR ChIP-seq data are derived from single experiments performed with 
organoid cultures of three pairs of CRC patients [57] or cultured LS180 cells [56]. For THP-1 cells the peak tracks display merged data from three biological repeats of 
ChIP-seq experiments with antibodies against VDR [55], PU.1 [84], CEBPA [85], H3K4me3 [80] and H3K27ac [80] as well as FAIRE-seq data [79] treated for 24 h 
with 1,25(OH)2D3 (1,25D) or vehicle (EtOH). The gene structures are shown in blue and vitamin D target genes are indicated in red. 
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4. Epigenetic basis of vitamin D signaling 
Chromatin is a complex of genomic DNA and nucleosomes, which are 
formed by histone proteins [68]. The epigenome of a cell represents the 
genome-wide information included in covalent and structural modifi-
cations of its chromatin [69]. The epigenome controls the access of 
transcription factors to their genomic binding sites [70] via changes in i) 
cytosine methylation, in particular at the sites of CpG islands, ii) more 
than 100 different types of post-translational modifications of histone 
proteins and iii) the 3-dimensional (3D) organization of the nucleus, 
such as topologically associated domains (TADs) [71]. For example, 
well-known markers for active chromatin are acetylated histone H3 
proteins at position lysine 27 (H3K27ac), while active transcription start 
site (TSS) regions are marked by H3K4me3 modifications [72]. 
The main regulatory regions of a gene are its TSS as well as the 
binding sites for transcription factors, referred as enhancers, which are 
found in a Gaussian-type distribution both up- and down-stream of the 
TSS (Fig. 1B) [73]. The expression of a vitamin D target gene is critically 
dependent on whether the TSS and at least one VDR-binding enhancer 
are located within accessible chromatin [74]. However, more than 90 % 
of the genomic DNA of a differentiated cell is not accessible, i.e., chro-
matin largely acts as an intrinsic repressor of gene expression [75,76]. 
Thus, the so-called “epigenetic landscape” of a differentiated cell type is 
restricted to some 100–200,000 genomic loci, most of which represent 
TSS and enhancer regions [73]. Interestingly, the transformation of a 
normal cell into a cancer cell includes multiple changes in this epige-
netic landscape [77]. This de-differentiation process results in an 
increased number of accessible chromatin regions [78]. Importantly, the 
epigenome can be modulated by environmental signals, such as 1,25 
(OH)2D3, i.e., in contrast to the genome the epigenome is dynamic. This 
implies the potential that vitamin D can re-arrange the epigenome of a 
tumor cell or its microenvironment [17]. 
The stimulation of leukemia cells (THP-1) with 1,25(OH)2D3 induces 
significant changes in the accessibility of their epigenome affecting 
nearly 9000 of 62,000 open chromatin loci [79]. Similarly, in the same 
cell line 550 of 22,998 genomic regions with H3K4me3 modifications 
and 2473 of 45,578 regions with H3K27ac marks respond significantly 
to a stimulation with 1,25(OH)2D3 [80]. Thus, vitamin D is able to 
modulate the activity of the epigenome of a cancer cell at more than 500 
promoter regions and some 2500 enhancer regions. VDR binding was 
detected at some 25 % of these chromatin regions, while the remaining 
1,25(OH)2D3-triggered sites of the epigenome seem to represent sec-
ondary effects of the nuclear hormone. VDR interferes with chromatin 
modifying proteins, such as KDM6B (lysine demethylase 6B), and the 
chromatin remodeler BRD7 (bromodomain containing 7). This happens 
via direct and indirect interactions of VDR with these proteins, such as 
being part of the same large protein complex in the nucleus [81,82] or 
the regulation of the genes encoding them [83], respectively. 
Like most other regular (“settler”) transcription factors, VDR func-
tionally interferes with “pioneer” transcription factors, such as PU.1 
(purine-rich box 1) [84], CEBPA (CCAAT/enhancer binding protein 
alpha) [85] and GABPA (GA binding protein transcription factor subunit 
alpha) [86] (Fig. 1B). Pioneer factors help regular transcription factors 
to access their genomic binding sites, i.e., in general they amplify the 
action of settler transcription factors [87]. For example, PU.1 and VDR 
work together in the process of monocyte and granulocyte differentia-
tion during hematopoiesis [88]. In THP-1 cells on 2/3 of all VDR binding 
sites also PU.1 is found [84]. Thus, on the genome-wide level PU.1 
shows a far higher rate of co-location with VDR as its traditional 
DNA-binding partner retinoid X receptor (RXR) [63]. 
Interestingly, at a subset of some 5% of all PU.1 sites 1,25(OH)2D3 
significantly supports the DNA binding of the pioneer factor, i.e., VDR 
can also act as an pioneer for PU.1 [84]. A similar functional interfer-
ence of vitamin D signaling was observed with the chromatin organizing 
protein CTCF (CCCTC-binding factor). In THP-1 cells, 1321 of the in 
total 23,658 CTCF binding sites are significantly affected by a 
stimulation with 1,25(OH)2D3 [79,89]. CTCF is one of the key proteins 
organizing the 3D structure of chromatin via binding to TAD anchors 
[90]. The anchors of these chromatin loops act as insulators towards 
neighboring TADs and are often conserved between tissues and species 
[91,92]. Vitamin D-sensitive CTCF sites affect the activity of some 600 
TADs and the vitamin D target genes included in them (Fig. 1B). Since 
the human genome is segregated into approximately 3000 TADs [93], 
some 20 % of all TADs seem to be sensitive to vitamin D. 
In summary, vitamin D influences the epigenome not only via 
changes of the chromatin accessibility status affecting VDR and pioneer 
factor binding, but also on the level of 3D chromatin structure. 
5. The vitamin D transcriptome and cancer 
Primary vitamin D target genes are modulated in their expression, i. 
e., in most cases they are up-regulated, when they co-locate on the same 
TAD with an enhancer region carrying a persistent and/or transient VDR 
binding site (Fig. 1C) [55]. We define primary vitamin D target as those 
genes that are significantly up- or down-regulated within 4 h after 
stimulation with 1,25(OH)2D3 [79]. VDR-activated enhancers activate 
via DNA looping RNA polymerase II (Pol II) on TSS regions leading to a 
stimulation mRNA production. This defines for most VDR sites and their 
target genes a chromosomal environment determining which gene is 
controlled by which receptor locus in its vicinity [94]. Transient sites, i. 
e., VDR loci that are occupied only at certain time points after ligand 
stimulation, modulate the vitamin D responsiveness of the epigenome, i. 
e., they support the actions of VDR molecules binding at persistent sites. 
Interestingly, the most critical attribute for the functional distinction of 
vitamin D-modulated TADs is the relative number of persistent and 
transient VDR sites [55]. For example, vitamin D target genes that are 
critical for immune function responding in an “on/off” modus and are 
primarily up-regulated by transient VDR loci (Fig. 1C) [94]. Persistent 
and transient VDR loci build up a specific local epigenomic environment 
that influences chromatin accessibility as well as histone modifications 
at TSS and enhancer regions. Thus, vitamin D-triggered changes of the 
epigenome and its consequences on the transcriptome are secondary 
effects of the activity of persistent and transient VDR sites acting on 
primary vitamin D target genes. 
The chromatin model of vitamin D signaling (Fig. 1B) describes 
vitamin D-triggered changes of the association of VDR and pioneer 
factors with their genomic sites affecting chromatin accessibility [14, 
60]. This results in a significant modulation of the expression of one or 
more primary vitamin D target genes located within the same TAD [95]. 
This implies that epigenetic changes occurring during the process of 
tumorigenesis influence the response of vitamin D target genes. How-
ever, this mechanism also bears the potential that a sufficient vitamin D 
status of a cancer patient may lead to epigenetic changes within tumor 
cells that affect critical target genes, such as the up-regulation of the cell 
cycle inhibitor CDKN1A (cyclin dependent kinase inhibitor 1A) [96,97], 
resulting in growth arrest (Fig. 2B). Thus, vitamin D-triggered changes 
of the epigenome in the genomic region of the CDKN1A gene keep the 
gene actively transcribed and allow its encoded protein to act as in-
hibitor of the cell cycle via binding to cyclin-cyclin-dependent kinase 
(CDK) complexes. 
Transcriptome-wide studies using microarrays and RNA sequencing 
(RNA-seq) in various cellular systems (including cell lines representing 
prostate, breast, ovarian, colorectal, squamous cell carcinoma and leu-
kemia [66]) identified a large set of primary and secondary vitamin D 
target genes. The latter are genes that are not directly regulated by VDR 
but are up- or down-regulated via transcription factors, chromatin 
modifiers or non-coding RNAs (ncRNAs) that are encoded by primary 
vitamin D target genes. Some of these are regulators of the cell cycle 
[98–100]. Common cellular processes targeted by vitamin D are cell 
cycle progression, apoptosis, cellular adhesion, oxidative stress, immune 
function and steroid metabolism. The most comprehensive description 
of the vitamin D-modulated transcriptome, as determined by RNA-seq 
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[101], was performed with leukemia cells (THP-1), which were stimu-
lated for 2.5, 4 and 24 h with 10 nM 1,25(OH)2D3 [79]. Statistics for 
differential expression initially indicated 1284 vitamin D target genes 
[79], while a re-analysis of this dataset reduced the number of genes to 
587 [55]. A bit more than half (311) of these genes are primary targets of 
vitamin D. Gene ontology analysis indicated that immune functions, 
such neutrophil signaling and inflammatory responses, are the most 
significant process regulated by these primary vitamin D target genes 
[95]. 
Transcriptomic studies in human CRC have been performed in 
immortal carcinoma cell lines, in primary patient-derived NFs, in 
cancer-associated fibroblasts (CAFs) and in organoids generated by 
normal and cancer stem cells (Table 1). The first microarray analysis 
showed a regulation of hundreds of genes after 4 and 48 h of 1,25 
(OH)2D3 treatment (10 nM) in SW480-ADH cells and a far lower number 
of genes in LS174 T cells [98]. Most target genes were up-regulated and 
their encoded proteins were preferentially involved in transcription, cell 
adhesion, DNA synthesis, apoptosis, redox status and intracellular 
signaling. In another microarray study performed in Caco-2 adenocar-
cinoma cells 12 genes (including CYP24A1 and others potentially 
involved in inhibition of cell proliferation) were found to be regulated 
upon 24 h treatment with 10 nM 1,25(OH)2D3 [100]. A later microarray 
study in LS180 cells with a 24 h treatment (10 nM) identified further 1, 
25(OH)2D3 target genes responsible for vitamin D catabolism, calcium 
and phosphate uptake, secondary bile acid metabolism and xenobiotic 
degradation and control of cell proliferation, such as MYC (MYC 
proto-oncogene, BHLH transcription factor) and FOS (Fos 
proto-oncogene, AP-1 transcription factor subunit)) [56]. As confirmed 
later by ChIP-seq analysis (3 h, 10 nM 1,25(OH)2D3) also in other cell 
systems, the majority of potential regulatory VDR binding sites are 
located far from the TSSs or in introns of their target genes. 
When considering the putative relevance of these transcriptomic 
studies, it is convenient to remind that cell lines used have complex and 
heterogeneous mutational landscapes following long-term culture. 
Moreover, in some cases these cell lines, such as Caco-2 cells, which are 
of colon origin but shows the phenotype of small intestinal epithelium, 
do not properly model the correct type of cancer. 
A strong regulatory effect of 1,25(OH)2D3 has been found in human 
colon stromal fibroblasts in a microarray study (48 h, 10 nM 1,25 
(OH)2D3) highlighting 958 genes (47 % up-regulated, 53 % down- 
regulated) in NFs and even 1489 genes (35 % up-regulated, 65 % 
down-regulated) in CAFs [67]. These gene lists partially overlap and 
most of the genes are involved in cell adhesion and migration, extra-
cellular matrix organization, blood vessel development, inflammatory 
response and cell communication. In an RNA-seq study in the immortal 
CCD-18Co human colon fibroblast cell line, 1,25(OH)2D3 (24 h, 10 nM) 
and WNT3A (WNT family member 3A) showed additive, partially 
overlapping effects on the transcriptome. Curiously, both agents inhibit 
the proliferation and migration capacities of CCD-18Co cells, while 1,25 
(OH)2D3 reduces but WNT3A increases the ability to contract collagen 
gels. The latter is a surrogate marker of the capacity to alter the extra-
cellular matrix, which is a hallmark of fibroblast activation. These ef-
fects were reproduced in patient-derived NFs and CAFs as well as in 
fibroblastic cell lines of several origins suggesting that 1,25(OH)2D3 and 
WNT3A regulate the gene expression and phenotype of human colon 
fibroblasts [102]. 
In patient-derived colon tumor organoids, a 96 h treatment with 10 
nM 1,25(OH)2D3 changes the RNA level of 1182 genes (643 up- 
regulated, 539 down-regulated), while in matched (same patient) 
normal organoids generated from healthy colon tissue the number of 
target genes was high as 2107 (943 up-regulated, 1164 down-regulated) 
[57]. Only 19.3 % of the genes in these lists overlap, which indicates that 
1,25(OH)2D3 regulates distinctly genes, e.g., related to cell stemness and 
differentiation, in the two types of organoids. In these and other tran-
scriptomic studies with 1,25(OH)2D3 over longer time periods, approx-
imately half of the target genes are down-regulated, i.e., the level of their 
Table 1 
1,25(OH)2D3 target genes in human colon and breast cancer cells. List of key 
representative genes regulated by 1,25(OH)2D3 in human colorectal and breast 
cancer or stromal cells indicating the process and signaling pathway they are 
involved in.  
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RNA transcripts are diminished by 1,25(OH)2D3. Gene repression by 
ligand-modulated nuclear receptors, such as VDR, is primarily an indi-
rect and/or post-transcriptional effect mediated by the products of pri-
mary target genes, such as transcription factors, chromatin modifiers 
and ncRNAs, through protein-protein interactions, signaling interfer-
ence or microRNAs (miRs). In contrast, in a process referred to as 
transrepression ligand-induced VDR directly represses primary vitamin 
D target genes, such as PTH (parathyroid hormone) in the parathyroid 
gland [103] and CYP27B1 in the kidneys [104]. 
Taken together, 1,25(OH)2D3 significantly changes the tran-
scriptome of healthy and malignant cell types at 1000–2000 genomic 
loci. Longer VDR ligand treatments lead to a higher percentage of sec-
ondary vitamin D target genes. However, a weakness of these studies is 
the heterogeneity of the cell types, their treatment protocols, such as 
number of replicates, duration and doses of 1,25(OH)2D3, and the sta-
tistical analyses making it difficult to translate their results to the 
identification of target genes. 
6. Impact of the immune system on the anti-cancer role of 
vitamin D 
There is large consensus that the modulation of the immune system is 
the most important extra-skeletal function of vitamin D [105,106]. 
Vitamin D stimulates the innate immune system in fighting more effi-
ciently against bacterial infections, such as tuberculosis [105], while it 
prevents overreactions of the adaptive immune system that may cause 
autoimmune diseases, such as multiple sclerosis [107,108]. On the basis 
of transcriptome-wide datasets from THP-1 cells (monocytes) and 
human peripheral blood mononuclear cells (PBMCs, a mixture of lym-
phocytes and monocytes) treated in vitro with 1,25(OH)2D3 as well as 
from PBMCs of individuals supplemented with a vitamin D3 bolus three 
groups of immune-related vitamin D target genes had been identified 
that represent the functions acute response to infection, infection in 
general and autoimmunity [109]. Interestingly, the vitamin D target 
genes can be differentiated in their epigenomic profile, such as the types 
of VDR-driven enhancers, as well as via the dynamics of their mRNA 
production. 
In general, vitamin D acts as an inducer of innate immunity, such as 
via the prominent up-regulation of the secreted anti-microbial peptide 
cathelicidin or plasma membrane-anchored glycoprotein CD14 [110]. 
CD14 functions as a co-receptor for the pattern recognition receptors 
Toll-like receptors (TLRs) [111] and delivers the pathogen-associated 
molecular pattern lipopolysaccharide to TLR4. Thus, the early 
response of monocytes and macrophages to vitamin D stimulation is a 
pro-inflammatory action [112]. In a later step vitamin D often shifts the 
polarization of macrophages from the pro-inflammatory, anti-tumor 
stage M1 to the immunosuppressive, pro-tumor M2 stage [113]. How-
ever, please note that the stages M1 and M2 are considered the extremes 
of a wide spectrum of plasticity of macrophages that is sensitive to 
epigenetic programing by vitamin D and its receptor VDR [60,114]. 
Thus, the anti-inflammatory and immunosuppressive functions of 
vitamin D are paired in certain cases with a pro-tumor effect. 
Vitamin D deficiency is associated with Crohn’s disease and ulcera-
tive colitis, which are the two predominant pathophysiological 
manifestations of inflammatory bowel disease [115,116]. The rates of 
inflammatory bowel disease are probably increasing due to modern 
lifestyles that affect the function of the gut microbiome via high levels of 
saturated fat and sugar in diet as well as the use of antibiotics [117]. 
Vitamin D is important for regulating the immunity of gut mucosa via 
the modulation of innate immune barrier function, gut epithelial 
integrity and the development and function of T cells [118,119]. Thus, 
vitamin D can prevent the onset of inflammatory bowel disease through 
the stabilization of microbiota homeostasis as well as ameliorates dis-
ease progression via anti-inflammatory immune responses. Interestingly, 
in persons with increase susceptibility for inflammatory bowel disease 
vitamin D deficiency is a contributing factor to the disease [120]. 
Knockout mice for CYP27B1 [121] as well as for VDR [122] show 
increased severity of experimentally-induced colitis that mimics in-
flammatory bowel disease, i.e., the inability to synthesize or recognize 1, 
25(OH)2D3 increases the severity of inflammatory bowel disease. 
Moreover, a treatment with 1,25(OH)2D3 improves the conditions of 
experimental colitis in murine models [115,123]. Accordingly, a low 
vitamin D status is a significant risk factor for the onset of CRC in in-
dividuals with inflammatory bowel disease [124]. 
Vitamin D mostly functions as a repressor of adaptive immunity, as it 
down-regulates the number of TH (T helper) 1 cells and increase that of 
TH2 cells and Treg (T regulatory) cells. However, the majority of these 
observations were made in experimental settings in which the cells were 
overstimulated. Thus, vitamin D may have a late role accelerating the 
resolution of inflammation following an early role in its initial activation 
[108,125–127]. Interestingly, a human intervention trial indicated that 
in the context of Western diet vitamin D3 supplementation increases the 
expression of inflammatory genes in colon cells, while additional sup-
plementation with calcium reverses this effect [128]. This may explain 
how a sufficient vitamin D status combined with high dietary calcium 
intake is linked to lower CRC risk. 
Vitamin D actions on the immune system involve the growth, dif-
ferentiation, activation/deactivation and eventually apoptosis of 
different types of immune cells, such as monocytes, dendritic cells and 
different types of T cells [129]. Importantly, immune and cancer cells 
use the same signal transduction pathways and genes for pushing their 
growth [130]. Therefore, it is possible that the anti-proliferative and 
differentiation- and apoptosis-inducing potential of vitamin D on cancer 
cells derives from pathways that were initially evolved for the growth 
control of immune cells, such as the up-regulation of the CDKN1A gene 
[131]. Moreover, these cell types are also found in the microenviron-
ment of tumors, i.e., some aspects of the anti-cancer effects of vitamin D 
could be explained by a modulation of the immune component of the 
microenvironment, which may be detrimental for cancer cells [132, 
133]. 
Tumor cells present at their plasma membrane antigens that can be 
specifically recognized by therapeutic monoclonal antibodies, such as 
Rituximab (anti-CD20) in B-cell lymphomas and Trastuzumab (anti- 
HER2, human epidermal growth factor receptor 2) in breast cancer. 
Vitamin D deficient patients are poor responders to this therapy [134, 
135]. This suggests another mechanism of 1,25(OH)2D3 with a potential 
anti-tumoral relevance in the clinic, which is the enhancement of the 
antibody-dependent cellular cytotoxicity of macrophages and natural 
killer cells. Nevertheless, the main impact of the immune system in 
explaining the anti-cancer effect of vitamin D may not be in controlling 
and reducing settled tumors but in preventing their establishment. In an 
healthy individual every day thousands of cells undergo alterations that 
change from a normal to a malignant phenotype, but most of them are 
detected in this early stage by cytolytic T cells and destroyed [136]. 
Thus, an activation of cytolytic T cells may be an effective way how 
vitamin D prevents cancer onset [137]. 
In summary, there are many mechanisms through which the prime 
action of vitamin D, the modulation of innate and adaptive immunity, 
affects the growth, differentiation and apoptosis of cancer cells and 
explains the anti-cancer action of the nuclear hormone. 
Table 1 (continued ) 
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7. Vitamin D and CRC 
A large number of mechanistic studies in vitro as well as in experi-
mental animals support the beneficial action of VDR agonists, which had 
been suggested by epidemiology data that linked vitamin D deficiency to 
high incidence and/or mortality by CRC [138]. The regulation of more 
than thousand vitamin D target genes in colon carcinoma cells, normal 
stem cells, cancer stem cells, stromal NFs and CAFs as well as immune 
cells of the tumor microenvironment in combination with the 
tumor-inhibitory effects of vitamin D in xenografted mice strongly 
indicate a protection against this form of neoplasia (Fig. 3). 
CRC is the best characterized solid neoplasia in terms of genetic al-
terations. Massive sequencing efforts have shown that over 94 % of 
primary and up to 96 % of metastatic colorectal tumors contain muta-
tions in genes that aberrantly activate the WNT/β-catenin signaling 
pathway [139,140]. Thus, mutually exclusive mutations of the genes 
APC (APC regulator of WNT signaling pathway), CTNNB1 (catenin beta 
1) and AXIN2 (axin 2) and less frequently of RSPO2/3 (R-spondin 2 and 
3), RNF43 (ring finger protein 43) and TCF7L2 (transcription factor 7 
like 2) in colon epithelial (probably stem) cells are considered the 
initiation of the tumorigenic process. 
1,25(OH)2D3 has two major effects on colon carcinoma cells: it in-
hibits the proliferation and promotes the differentiation through several 
mechanisms including i) the induction of VDR binding to β-catenin 
within the cell nucleus that prevent the formation of transcriptionally 
active TCF7L2/β-catenin complexes, ii) the up-regulation of the protein 
CDH1 (cadherin 1, also called E-cadherin) at the plasma membrane 
where it attracts the newly synthesized β-catenin protein and iii) the 
induction of the gene DKK1 (Dickkopf WNT signaling pathway inhibitor 
1) [141–143]. 
An important anti-proliferative mechanism of 1,25(OH)2D3 is the 
inhibition of the MYC gene, which is a major cell cycle regulator being 
induced by the WNT/β-catenin pathway and over-expressed in CRC as 
well as in many other cancer types. While nearly all CRCs have changes 
in MYC target genes, vitamin D represses the MYC gene directly by VDR 
binding to its promoter [144] and indirectly via inhibition of the 
WNT/β-catenin pathway [141], the induction of its antagonistic partner 
MAD/MXD1 of MYC [145] and the enhancement of its FBW7 E3 
ligase-mediated ubiquitination and subsequent proteasomal degrada-
tion of the MYC protein [146]. 1,25(OH)2D3 regulates also other genes 
encoding cell cycle proteins or members of mitogenic pathways 
(Table 1). Another mode by which 1,25(OH)2D3 reduces cell prolifera-
tion is the interference of signaling by mitogens. Vitamin D reduces the 
expression and activity of the EGFR gene and also represses the SPRY2 
(sprouty RTK signaling antagonist 2) gene, which encodes an activator 
of intracellular EGF signaling [147–149]. Likewise, 1,25(OH)2D3 in-
hibits signaling by insulin growth factor (IGF) 2 protein. 
These findings show that 1,25(OH)2D3 is a multi-level inhibitor of 
colon carcinoma cell proliferation via controling a variety of genes and 
several mitogenic signaling pathways. Conceivably, this anti-tumoral 
mechanism is a secondary effect of the evolutionary selection of 1,25 
(OH)2D3 as a homeostatic regulator of the organism through the control 
of a large proportion of the human genome. Supporting this idea, in 
colon carcinoma cells 1,25(OH)2D3 also regulates genes involved in 
apoptosis, angiogenesis and migration/invasiveness as well as in cell 
adhesion and differentiation (Table 1) [98,150,151]. 
Remarkably, epigenetic regulators, such as KDM6B and other histone 
demethylases [83,152] as well as CST5 (cystatin D) are also under the 
control of 1,25(OH)2D3 [153,154]. CST5 is a member of the cathepsin 
gene family encoding a multifunctional protein with protease activity in 
lysosomes and gene regulatory action within the cell nucleus. Moreover, 
several genes encoding enzymes and inhibitors of the 
ubiquitin-proteasome system are modulated by vitamin D in colon car-
cinoma cells suggesting that 1,25(OH)2D3 has a role in the 
post-translational control of gene expression [155]. Additional path-
ways affected by liganded VDR are detoxification and 
immunomodulation-related signaling, the latter probably both in car-
cinoma cells and in immune cells of the tumor microenvironment 
(Table 1) [102,108]. 
An indirect but potent mechanism of controling the phenotype of 
colon carcinoma cells by 1,25(OH)2D3 is the regulation of miR-22, 
which contributes to the anti-proliferative and migratory actions of 
vitamin D and has also anti-tumor activity in several cancers [156]. 
The induction of an epithelial differentiated phenotype is a second 
major effect of 1,25(OH)2D3 in colon carcinoma cells. A key mechanism 
is the up-regulation of the CDH1 gene [121], the encoded protein of 
Fig. 3. Vitamin D effects in CRC. The scheme shows the topographic distribution of the cell types in the colon crypt. Effects of 1,25(OH)2D3 on the different cell 
types (tumor and stromal) in a colon neoplasia and in adjacent normal tissue. Homeostatic effects on normal cells and protective effects on tumor cells are indicated. 
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which is the main component of adherens junctions being the most 
important structure responsible for intercellular adhesion in epithelia. 
The promotion of strong cell-to-cell adhesion, which reduces their ca-
pacity to proliferate, is further supported by the induction of other 
genes, OCLN and TJP1, coding for components of additional adhesion 
structures, such as tight junctions and desmosomes [121] (Table 1). 
Remarkably, a detailed study of the induction of the CDH1 gene 
revealed a rapid, non-genomic signaling pathway triggered via extra-
nuclear VDR [157]. 1,25(OH)2D3 increases cytosolic Ca2+ concentration 
in a transcription-independent way by favoring its entry from the 
external medium, which causes the cascade activation of RHOA (Ras 
homolog family member A), ROCK1 (Rho associated coiled-coil con-
taining protein kinase 1) and the kinases MAPK14 (mitogen-activated 
protein kinase 14) and RPS6KA5 (ribosomal protein S6 kinase A5). 
Importantly, the induction of this pathway is necessary for the gene 
regulatory action of 1,25(OH)2D3 within the cell nucleus in a variety of 
cell types. This indicates a dual role of VDR and the convergence of 
non-genomic and genomic 1,25(OH)2D3 signaling pathways [157]. 
Thus, 1,25(OH)2D3 has a key role in the biology of colon epithelial cells 
counteracting the genetic and epigenetic alterations that promote the 
apparition of colon carcinomas. 
A large proportion of advanced CRC cases do not express the VDR 
gene, which is due to the up-regulation of the transcription factors 
SNAI1 (snail family transcriptional repressor 1) and SNAI2 that bind and 
block the VDR promoter region [158,159]. This suggests that VDR ag-
onists have a protective effect in the prevention and early stages of CRC. 
However, a recent study [67] analyzing more than 600 CRC biopsies 
revealed that high VDR expression in CAFs associates with better clinical 
patient outcome. Moreover, 1,25(OH)2D3 imposes in primary CAF cul-
tures a gene signature (48 genes) that is associated with longer patient 
survival [67]. Accordingly, 1,25(OH)2D3 regulates in these cells 
signaling pathways that are linked to a phenotype of activated fibro-
blasts by modulating of extracellular matrix and 
cytokine/chemokine-mediated cell migration and communication. As a 
result, 1,25(OH)2D3 attenuates two pro-tumoral effects of CAFs, which 
are their capacity to contract/alter the collagen gel and to promote the 
migration of carcinoma cells [67]. 1,25(OH)2D3 reprograms stromal fi-
broblasts towards a less pro-tumoral phenotype as already shown for 
liver and pancreas cancer [132,160]. This indicates that the beneficial 
actions of VDR agonists also affect stromal cells of the tumor microen-
vironment. Thus, CRC patients with VDR-negative carcinoma cells may 
still benefit from vitamin D treatment. 
Based on the concept of Tomasetti and Vogelstein [161] 2/3 of all 
cancer mutations are based on replication errors, primarily of normal 
adult stem cells. A large part of these mutations are due to extrinsic 
factors, i.e., they are based on lifestyle decisions, such as smoking and 
diet choice. However, until recently the effect of vitamin D on 
non-hematopoietic stem cells had not been studied. Therefore, a recent 
study [57] using organoids generated with healthy colon tissue from 
CRC patients became very important, as it indicated that 1,25(OH)2D3 
inhibits cell proliferation and maintains the stem cell phenotype by 
increasing the expression of several stemness-related genes (LGR5 
(leucine rich repeat containing G protein-coupled receptor 5), SMOC2, 
LRIG1, MEX3A, MSI1, PTK7). In contrast, in matched tumor organoids of 
the same patients 1,25(OH)2D3 promotes cell differentiation with only 
minor changes in stemness genes. Moreover, vitamin D also causes a 
variable inhibitory effect on cell proliferation and the repression of 
genes linked to the tumorigenesis process. In contrast to carcinoma cells 
with an overactivated WNT/β-catenin pathway, 1,25(OH)2D3 does not 
affect WNT target genes in stem cell-derived organoids. In the latter, this 
signaling pathway plays a major role in the maintenance of stemness 
with EGF acting as the main mitogen. Thus, 1,25(OH)2D3 contributes to 
the preservation of the undifferentiated phenotype of crypt bottom adult 
stem cells and their basal level of proliferation, but, importantly, it at-
tenuates their transformation into cancer stem cells. For example, 
feeding mice a purified rodent Western-style, low vitamin D diet 
perturbs intestinal cell maturation and WNT signaling and causes spo-
radic colon and small intestinal tumors. The diet acts as extrinsic factor 
and associates with extensive transcriptional reprograming, such as 
decreasing the number of mouse Lgr5high intestinal stem cells 
[162–164], and supports the role of vitamin D in controlling intestinal 
stem cells. Thus, the anti-cancer effect of vitamin D, in particular on 
CRC, may be primarily caused by its effects on adult stem cells. 
Taken together, vitamin D modulates an ample array of signaling 
pathways in the diverse cell types involved in CRC (Fig. 3 and Table 1). 
Both the homeostatic nature of those promoted in normal adult stem 
cells and NFs and the anti-tumor nature of those induced in carcinoma 
cells, CAFs and cancer stem cells strongly indicate a strong, multi-level 
protective action of vitamin D against CRC. 
8. Vitamin D and breast cancer 
Data on the association of vitamin D and breast cancer incidence 
and/or mortality are inconclusive and less clear than for CRC [165]. 
However, two recent meta-analyses suggest a protective relationship 
between 25(OH)D3 serum levels (not vitamin D intake, emphasizing the 
importance of individual genetics and metabolism) and breast cancer 
risk [166,167]. Some studies [166], but not others [167], have found a 
preferential effect in pre-menopausal women. The controversial results 
reported may be, at least in part, due to the heterogeneity of breast 
cancer, which comprises several pathological and genetic subtypes. 
Interestingly, the triple-negative breast cancer (TNBC) subtype, which is 
characterized by the lack or low tumor expression of ER, PR and HER2 
protein (ER− , PR− , HER2− ) and a poor prognosis, may preferentially 
benefit from the protective effect of vitamin D [167,168]. Supporting 
this, TNBCs showing positive VDR staining correlate inversely with bad 
pathological features and directly with increased overall survival [169]. 
As for CRC, studies in cultured cells and animal models of breast 
cancer support a protective effect of VDR agonists, which appears to 
result from direct effects on tumor cells rather than on systemic actions 
or effects on stromal cells of the microenvironment [170]. Thus, treating 
breast cancer cell lines with 1,25(OH)2D3 induces anti-proliferative 
[171] as well as pro-apoptotic effects [172,173]. The former is linked 
to the suppression of growth stimulatory signals and genes (MYC and 
genes coding for cyclins and CDKs) and the potentiation of growth 
inhibitory signals and genes, whilst the latter is explained by BCL2 
(BCL2 apoptosis regulator) family proteins. Moreover, 1,25(OH)2D3 fa-
vors the differentiated, non-invasive epithelial phenotype of breast 
tumor cells by both inducing genes, such as CDH1, while repressing 
those encoding for N- and P-cadherins (CDH2 and CDH3) and others 
[174–176] (Table 1). Thus, as in CRC, MYC and CDH1 seem to be crucial 
target genes of 1,25(OH)2D3 in breast carcinoma cells. 
Other studies, however, proposed tumor non-autonomous effects of 
vitamin D on breast cancer. For example, 1,25(OH)2D3 reduces the 
adverse effects of obesity on breast cancer by acting on pathways both 
within breast cancer cells and surrounding adipocytes by suppressing 
estrogen synthesis and signaling via the control of prostaglandin E2 
synthesis by PTGS2 (prostaglandin-endoperoxide synthase 2) and 
degradation, and the inhibition of ER and PTGER2 (prostaglandin E 
receptor 2) and CYP19A1 (aromatase) [177,178]. Giving the important 
role of estradiol promoting the proliferation of breast cancer cells at least 
at early stages of tumor development, these effects on estrogen signaling 
may protect against breast cancer at the initial steps. In addition, 1,25 
(OH)2D3 enhances AMPK (adenosine monophosphate-activated protein 
kinase) signaling and restores the adipokine profile by decreasing leptin 
signaling and stimulating adiponectin signaling that are dys-regulated in 
response to diet-induced obesity in both tumor cells and surrounding 
adipose tissue. 
Finally, 1,25(OH)2D3 inhibits spheroid formation by mouse breast 
tumor-initiating cells by down-regulating ER [179]. Likewise, 1,25 
(OH)2D3 inhibits mammosphere formation in cultures of MCF10DCIS 
and SUM159 breast cancer cell lines by down-regulating the expression 
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of stem cell markers and several NOTCH pathway genes [180]. 
In summary, the effects of vitamin D on breast cancer are partially 
similar to but overall less convincing than those on CRC. Moreover, the 
effect, if any, of 1,25(OH)2D3 on authentic human breast cancer stem 
cells remains to be elucidated. 
9. Vitamin D and prostate cancer 
The association between vitamin D status and prostate cancer is 
much less compelling than those for colorectal or breast cancer sug-
gesting that not all tissues or cancer cell types respond identically. While 
some studies found a direct relation between circulating 25(OH)D3 and 
prostate cancer risk or mortality, others did not, and even a few reported 
that high levels of 25(OH)D3 are associated with increased risk, alto-
gether leading to inconclusive meta-analyses [181,182]. A limited 
number of interventional clinical trials using vitamin D compounds as 
single agents or in combination have been seriously criticized for bad 
design and flawed conclusions [183]. Still, data from pre-clinical studies 
on the effect of vitamin D in prostate cells and animal models do not 
differ much from those in other cancer types. In addition to the usual 
anti-proliferative and apoptotic-sensitization effects, 1,25(OH)2D3 has 
in prostate cancer regulatory actions on PTGS2 and other genes of the 
prostaglandin pathway as well as on IL6 suggesting an 
anti-inflammatory effect [184]. Moreover, 1,25(OH)2D3 activates in 
prostate cancer cells metabolic enzymes, such as CYP3A4, CYP3A5, 
UGT2B15/17 and SULT2B1, that may reduce the availability of andro-
gens acting as mitogens in these cells. 
A microarray study in the human non-transformed RWPE1 prostate 
epithelial cell line showed that 1,25(OH)2D3 regulates a high number of 
genes suggestive of the suppression of cancer- and inflammation-related 
signaling pathways (WNT, NOTCH, NF-κB, IGF1, IL1, IL6, IL17) and the 
induction of protection from oxidative stress [185]. Concordantly, in the 
TgAPT121 mouse model of prostate cancer dietary vitamin D reduces the 
apparition of adenocarcinomas whereas the loss of the Vdr gene accel-
erates the early stages of prostate carcinogenesis [53]. In this system, 
microarray and ChIP-seq analysis identified thousands of target genes, 
some of which are involved in cell cycle and proliferation (FOS, EGR1, 
MAPK8, HGF, MYC), apoptosis (FOXO1, SRF, CALM2), cell adhesion 
(EPHB1, EPHA2, MLCK), immune response (CCL16, IL6, IFNG) and gene 
transcription/expression (HIF1A, SMAD3, CREB1, CREM, CBF1, ESR1). 
Interestingly, in another model of prostate cancer, TRAMP mice, early 
treatment with vitamin D slowed androgen-stimulated tumor progres-
sion by reducing tumor cell proliferation and inducing E-cadherin but in 
long-term increased distant organ metastasis [186]. 
Taken together, prostate cancer is complex with an intricate hor-
monal regulation and multiple cell types involved. Still much work is 
needed to elucidate the mechanisms and potential utility of vitamin D in 
this neoplasia. 
10. Vitamin D and hematological malignancies 
As it happens in solid tumors, patients with hematological malig-
nancies, such as leukemias, lymphomas and multiple myeloma, usually 
have a low vitamin D status being associated with a poorer prognosis 
[187–190]. As in other cancer cell types, VDR agonists inhibit prolifer-
ation (AML, B cell acute lymphoblastic leukemia, follicular non--
Hodgkin’s lymphoma), sensitize to apoptosis promoted by signals 
including other anti-tumor therapies (AML, cutaneous T lymphoma, 
multiple myeloma, diffuse large B cell lymphoma, B cell chronic lym-
phocytic leukemia), induce differentiation (AML, follicular non--
Hodgkin’s lymphoma) and usually decrease the production of 
pro-inflammatory cytokines [191]. 1,25(OH)2D3 decreases the activa-
tion of the Janus kinase (JAK)-signal transducers and activators of 
transcription (STAT) signaling pathway, as revealed by diminution of 
the level of phospho-STAT3 and phospho-STAT1. This pathway is 
commonly overactivated in leukemia and lymphoma cells due to 
mutation in JAKs or STATs or by abnormally high cytokine signaling. As 
a consequence, 1,25(OH)2D3 decreases the production of the cytokines 
IFNG (interferon gamma), TNF (tumor necrosis factor) and several in-
terleukins [192]. 
AML is a heterogeneous group of leukemias that result from clonal 
transformation of hematopoietic precursors through the acquisition of 
chromosomal rearrangements and multiple gene mutations. As AML 
cells are proliferatively immature, differentiation therapy is potentially 
effective for initiation of terminal differentiation and represents a sup-
plementary approach for the treatment of neoplastic disease in combi-
nation with existing treatment modalities [193]. Importantly, 1,25 
(OH)2D3 initiates differentiation in AML cell lines, such as HL60, which 
are predominantly neutrophilic promyelocytes. Treatment of HL60 cells 
with 1,25(OH)2D3 results in a reduced proliferation and enhanced dif-
ferentiation along the monocyte-macrophage pathway possibly by 
mechanisms involving the up-regulation of CEBPD [194,195]. More-
over, together with the pioneer factors CEBPA and PU.1 VDR is the key 
regulator of the differentiation of monocytes and granulocytes [88] 
probably via the induction of the CDKN1A gene [196]. Interestingly, in a 
zebrafish model it had been shown that vitamin D regulates the number 
of embryonal hematopoietic stem cells [44]. This observation was 
confirmed ex vivo with human hematopoietic stem cells possibly via the 
induction of the gene CXCL8 (C-X-C motif chemokine ligand 8) that is 
known as a primary vitamin D target [197]. This suggests that vitamin D 
first pushes the growth of hematopoietic stem cells and then induces 
their differentiation into myeloid cells. Accordingly, in the context of 
hematopoietic stem cell transplants vitamin D deficiency is known to be 
associated with increased complications, such as graft-versus-host dis-
ease, delayed time to neutrophil engraftment and overall survival [198, 
199]. 
A recent mice study showed that Vdr deficiency in hematopoietic 
precursors causes an increase in the expression of the genes MECOM 
(MDS1 and EVI1 complex locus), HOXA9 (homeobox A9) and MEIS1 
(meis homeobox 1) suggesting the induction of an immature phenotype 
and, concordantly, of the number leukemia stem cells and normal he-
matopoietic stem cells [200]. 
In summary, VDR is a new genetic modifier contributing to the 
expression of different subtypes of acute myeloid leukemia, i.e., vitamin 
D plays an important role in normal but also in pathological 
hematopoiesis. 
11. Conclusion 
Epigenomic and transcriptomic analyses as well as numerous 
experimental studies in a variety of cancer systems provided large sets of 
strong data that jointly indicate a protective action of vitamin D 
signaling against several types of cancer. Most convincing molecular 
data exist for CRC and AML. This results from the regulation of a high 
number of genes that control the proliferation, survival, differentiation, 
migration and communication of cancer cells and stromal cells, such as 
fibroblasts, adipocytes, immune and endothelial cells. Conceivable, the 
lack of concordant positive clinical data in large randomized controlled 
trials may be due to lack of sub-analysis of disease cohorts (e.g., the 
selection and analysis of patients) as well as short follow-up. Moreover, 
the careful characterization of disease subgroups should lead to more 
consistent data as shown for TNBC. Vitamin D is a major regulator of 
signaling in human cells, which displays a long list of protective ho-
meostatic effects in cultured cells and animal models of cancer. Thus, it 
contributes to maintain and defend the normal physiology of the or-
ganism against the apparition and development of neoplasias. The 
identification of the optimal clinical use of the vitamin D system is a task 
demanding continuous efforts. 
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